Each ADA deficiency patient (n = 3) screened was on some form of enzyme replacement treatment (ERT) for their disorder and data suggests the form of the treatment impacted the ability of Immuno-SRM to identify patients (Figure 2). This evidence concerns the gene ADA and hyperinsulinemic hypoglycemia, familial, 4.